Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	84.71	128.06	191.44	113.56	144.9
Short-Term Investments	200.45	88.92	9.95	116.04	74.92
Cash & Short-Term Investments	285.16	216.97	201.39	229.6	219.81
Cash Growth	31.43%	7.74%	-12.28%	4.45%	-23.49%
Accounts Receivable	5.94	1.67	-	-	-
Other Receivables	1.97	0.7	0.06	0.59	0.13
Total Trade Receivables	7.91	2.37	0.06	0.59	0.13
Other Current Assets	12.63	13.41	13.88	13.89	9.28
Total Current Assets	305.7	232.76	215.34	244.07	229.22
Net Property, Plant & Equipment	6.25	8.25	12.43	11.43	9.08
Long-Term Investments	106.26	29.82	-	-	-
Other Long-Term Assets	0.23	0.72	0.57	0.57	0.57
Total Assets	418.43	271.56	228.34	256.07	238.87
Accounts Payable	4.94	2.5	1.7	0.77	2.39
Accrued Expenses	41.04	18.57	13.82	15.75	14.75
Unearned Revenue	11.9	18.99	15.31	14.88	-
Total Current Liabilities	57.88	40.06	30.82	31.39	17.14
Other Long-Term Liabilities	8.1	2.48	37.96	39.82	3.95
Total Long-Term Liabilities	8.1	2.48	37.96	39.82	3.95
Total Liabilities	65.98	42.53	68.78	71.22	21.09
Common Stock	0.01	0.01	0	0	0
Additional Paid-in Capital	849.62	720	561.43	483.17	414.02
Accumulated Other Comprehensive Income	0.54	-0.15	-0.02	-1.18	-0.17
Retained Earnings	-497.72	-490.83	-401.85	-297.15	-196.08
Shareholders' Equity	352.46	229.02	159.57	184.85	217.78
Total Liabilities & Equity	418.43	271.56	228.34	256.07	238.87
Net Cash (Debt)	285.16	216.97	201.39	229.6	219.81
Net Cash Growth	31.43%	7.74%	-12.28%	4.45%	-23.49%
Net Cash Per Share	4.82	4.02	4.58	5.90	5.98
Book Value	352.46	229.02	159.57	184.85	217.78
Book Value Per Share	5.95	4.24	3.63	4.75	5.93
Tangible Book Value	352.46	229.02	159.57	184.85	217.78
Tangible Book Value Per Share	5.95	4.24	3.63	4.75	5.93

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q